Vertical Farming for Medicinal Cannabis Market Size & Share 2026-2035
Market Size - By Growing Technology (Hydroponics, Aeroponics, Aquaponics), By Component (Hardware, Software, Services), By Facility Structure (Building-Based Facilities, Container-Based Facilities), and By End-User Type (Licensed Pharmaceutical Producers (LPs), Contract Cultivation Organizations (CCOs), Academic & Research Institutions, Government & State-Licensed Cultivators), Growth Forecast. The market forecasts are provided in terms of revenue (USD Million).
Report ID: GMI16069
|
Published Date: June 2026
|
Report Format: PDF
Download Free PDF
Authors:
Kiran Puldinidi, Kunal Ahuja
Vertical Farming for Medicinal Cannabis Market Size
The global vertical farming for medicinal cannabis market was valued at USD 331 million in 2025. The market is projected to advance from USD 387 million in 2026 to USD 1.57 billion by 2035, compounding at a CAGR of 16.9% over the forecast period, according to the latest report published by Global Market Insights Inc.
Vertical Farming for Medicinal Cannabis Market Key Takeaways
Market Size & Growth
Regional Dominance
Key Market Drivers
Challenges
Opportunity
Key Players
This growth trajectory reflects the accelerating regulatory formalization of pharmaceutical-grade cannabis cultivation across Europe and key export-oriented emerging markets, where GMP and GACP mandates are converting controlled environment agriculture from a niche production model into the baseline standard for licensed medicinal cannabis supply chains. Structurally, the hardware component continues to represent the dominant revenue category at 59.5% of 2025 market revenue, while the software segment is advancing at a materially higher CAGR of 19.4%, signaling a progressive migration of value creation toward digital cultivation intelligence and GMP compliance automation platforms. At the end-user level, Licensed Pharmaceutical Producers (LPs) account for 65% of 2025 revenue, while Contract Cultivation Organizations (CCOs) - advancing at 20% CAGR - are emerging as the fastest-growing end-user cohort, mirroring the CRO/CMO outsourcing model in pharmaceutical manufacturing.
Key Drivers
Drivers Impact Analysis
Driver
Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
EU Legalization & GMP Mandates
+4.5–5%
Europe (primary), Global (secondary)
Short term (≤ 2 years)
Pharmaceutical-Grade Consistency Demand
+3–3.5%
Europe, North America, Australia
Medium term (2–4 years)
LED & Climate Technology Cost Reduction
+2–2.5%
Global
Medium term (2–4 years)
Export-Oriented Vertical Farm Development
+1.5–2%
Latin America, MEA, Asia Pacific
Long term (≥ 4 years)
EU Legalization & GMP Mandates
Germany's Medicinal Cannabis Act (MedCanG), enacted effective April 1, 2024, and the European Medicines Agency's revised Good Agricultural and Collection Practice (GACP) guidelines represent the most consequential demand catalysts in the global vertical farming for medicinal cannabis market. [1]European Medicines Agency, https://www.ema.europa.eu[2]German Federal Institute for Drugs and Medical Devices (BfArM), https://www.bfarm.de Germany has transitioned from an import-dependent market to a regulated cultivation and export economy, with licensed producers required to comply with EU-GMP standards before their product can enter the pharmaceutical distribution channel. This regulatory shift has created a bifurcated supply landscape: operators with GMP-certified vertical infrastructure are gaining access to premium pharmaceutical channels, while non-compliant producers face progressive exclusion from high-value European markets. The Netherlands, France, and the United Kingdom are advancing parallel frameworks, with the Netherlands maintaining the longest-established medicinal cannabis program under the Office of Medicinal Cannabis (OMC), providing a tested regulatory template that neighboring markets are increasingly referencing in their own legalization architectures. [3]European Monitoring Centre for Drugs and Drug Addiction, https://www.emcdda.europa.eu
Pharmaceutical-Grade Consistency Demand
Pharmaceutical buyers and hospital pharmacies sourcing medicinal cannabis for clinical applications require batch-level uniformity in cannabinoid profiles - specifically THC:CBD ratios, minor cannabinoid concentrations, and absence of microbial and pesticide contamination that outdoor and conventional greenhouse production cannot reliably deliver. Vertical farming, through the precise control of lighting spectrum, temperature, humidity, CO₂ concentration, and nutrient delivery, enables cultivators to maintain cannabinoid profile consistency across successive batches at a pharmaceutical specification level. This demand signal is accelerating the market transition: EU health regulators and hospital procurement frameworks are progressively tightening acceptance criteria, with several European university hospital networks now explicitly requiring GMP certification documentation for all medicinal cannabis procurement. The underlying structural consequence is that vertical farming is ceasing to be a premium-tier production option and is becoming a prerequisite for pharmaceutical channel access across European markets.
LED & Climate Technology Cost Reduction
Next-generation LED horticultural lighting systems, combined with advances in HVAC and climate control efficiency, are reducing the energy operating expenditure of vertical cannabis cultivation by an estimated 30-40% compared to earlier-generation high-pressure sodium (HPS) installations. [4]International Energy Agency, https://www.iea.org This cost reduction is material given that energy typically represents 25–35% of total operating costs in a GMP-certified vertical cannabis facility, making lighting technology advances a direct margin lever for both facility operators and technology vendors. Fluence's SPYDR 3 series and Heliospectra's Mitra X system represent two commercial benchmarks in spectrum-optimized LED horticulture lighting designed specifically for high-density medicinal cannabis canopy applications. The second-order effect is a reduction in the financial payback period for new GMP vertical cannabis infrastructure investment, progressively improving the business case for capital deployment among mid-sized licensed producers that had previously evaluated vertical farm construction as prohibitively capital-intensive.
Export-Oriented Vertical Farm Development
Colombia, Thailand, and South Africa are emerging as strategically positioned, low-cost GMP-certified cultivation hubs serving European and Australian pharmaceutical import markets. [5]United Nations Office on Drugs and Crime, https://www.unodc.org Colombia's regulated medicinal cannabis export framework, formalized under Law 1787/2016 and subsequently expanded through Resolution 315/2020, has attracted GMP vertical farm investment targeting EU pharmaceutical market access at a substantially lower land and labor cost base than European facilities. Thailand's narcotics regulatory reform has catalyzed a licensed cultivation industry specifically oriented toward GMP pharmaceutical export, with the Thai Food and Drug Administration establishing a dedicated medicinal cannabis GMP certification pathway aligned with international pharmaceutical standards. South Africa's SAHPRA licensing framework for medicinal cannabis cultivation is attracting vertically integrated investment from operators targeting both the growing MEA institutional market and the European import channel. [6]South African Health Products Regulatory Authority (SAHPRA), https://www.sahpra.org.za
Key Challenges
Restraints Impact Analysis
Challenge
Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
High Capex for GMP-Grade Facilities
−2.5–3%
Global
Short term (≤ 2 years)
Energy-Intensive Operations & OPEX Pressure
−1.5–2%
Europe (primary), Global (secondary)
Medium term (2–4 years)
Multi-Jurisdictional Licensing Complexity
−1–1.5%
Global
Long term (≥ 4 years)
High Capex for GMP-Grade Facilities
Purpose-built EU-GMP vertical cannabis facilities require construction, cleanroom integration, HVAC validation, water purification systems, and process control infrastructure that collectively place capital requirements in the range of €10 million to €50 million or more before the first commercial harvest. [7]World Health Organization, https://www.who.int This capital requirement constitutes a structural barrier for mid-sized and emerging licensed producers lacking access to institutional capital markets or operating in jurisdictions where lending institutions have limited familiarity with the medicinal cannabis sector's risk and revenue profile. The mitigation pathway that has emerged is the contract cultivation organization model, where operators outsource cultivation to pre-built, GMP-certified CCO facilities - reducing asset-light producer exposure to upfront infrastructure cost while accessing pharmaceutical supply chain compliance. Technology financing options from vertical farm systems providers, including structured leasing programs offered by Agrify Corporation for its Vertical Farming Units (VFUs), are also beginning to reduce the effective upfront capital burden for qualified operators.
Energy-Intensive Operations & OPEX Pressure
GMP-compliant vertical cannabis cultivation facilities operate continuously controlled environments - with 18–24 hour lighting cycles during vegetative growth, HVAC-maintained temperature and humidity profiles, and continuous CO₂ management creating a structurally high electrical load profile that generates substantial ongoing energy costs. Rising industrial electricity prices across Europe, driven by energy market dislocations and the structural transition away from baseload fossil fuel generation, have elevated OPEX pressure specifically for European vertical cannabis operators. Several German and Dutch operators have disclosed industrial electricity costs in the range of USD 0.15–USD 0.25 per kWh, creating a meaningful financial headwind for facilities that have not completed LED retrofit programs or installed renewable energy integration infrastructure. The mitigation pathway is bifurcated: large operators with institutional capital access are investing in on-site photovoltaic generation and battery storage to reduce grid exposure, while technology providers are competing on progressively higher efficiency metrics per watt of installed lighting capacity.
Multi-Jurisdictional Licensing Complexity
Licensed producers seeking to operate across multiple national markets face regulatory approval timelines ranging from 12 to 36 months per jurisdiction, with each market's GMP certification body applying its own inspection protocols, documentation standards, and compliance timelines. The European market alone comprises multiple overlapping regulatory frameworks EMA GACP guidelines (revised 2025), national competent authority GMP inspections, and in several markets, specific national medicinal cannabis legislation that creates additional local compliance layers. For export-oriented cultivators targeting both European and Australian pharmaceutical markets, the compliance overhead of maintaining parallel certification under EU-GMP and TGA (Therapeutic Goods Administration) standards represents a material administrative and financial burden. The second-order effect is that licensing complexity creates a structural competitive advantage for operators that have already secured multi-market certification, raising the effective entry barrier for new cultivators seeking pharmaceutical channel access.
Vertical Farming for Medicinal Cannabis Market Trends
EU-GMP and GACP Compliance as the New Market Access Baseline
The European pharmaceutical regulatory architecture for medicinal cannabis has undergone a fundamental reconfiguration over the 2023–2025 period, shifting from a framework where GMP compliance was a competitive differentiator to one where it functions as the minimum requirement for pharmaceutical channel access. The European Medicines Agency's revised GACP guidelines, updated in 2025, establish explicit documentation requirements for controlled environment cultivation - including continuous environmental monitoring records, batch traceability systems, and cleanroom-compliant facility design parameters - that are structurally incompatible with outdoor or uncontrolled greenhouse cultivation architectures. Germany's MedCanG, effective April 1, 2024, removed cannabis from the German Narcotics Act and established a licensed pharmaceutical supply framework that requires EU-GMP certification at the cultivation stage, creating an institutional demand mandate with no precedent in the global cannabis market's regulatory history.
The commercial consequence is measurable in facility investment patterns: Bedrocan International in the Netherlands, the world's first EU-GMP certified medicinal cannabis producer, has operated at pharmaceutical-grade cultivation standards for over two decades, and its facility architecture - characterized by precisely controlled indoor environments, pharmaceutical-grade water purification, and extensive environmental monitoring systems - is now functioning as the reference standard for new entrant facility design across Germany, France, and the United Kingdom. Tilray Deutschland GmbH's 6,000 m² EU-GMP indoor facility in Germany, which exports to more than 20 countries, and Avextra Pharma GmbH's 10,000 m² GMP facility across Germany and Portugal represent the current commercial benchmark for vertically integrated pharmaceutical cannabis cultivation in the European market.
Timeline: This trend is operating over the short-to-medium term (1–4 years), as the remaining non-compliant European cultivators either invest in GMP vertical infrastructure or exit pharmaceutical supply channels. The quantified commercial impact is evident in the facility investment pipeline: GMP-certified vertical farm construction activity across Germany and the Netherlands has accelerated materially in the 24 months since Germany's MedCanG enactment, with multiple new licensed producers commissioning purpose-built EU-GMP indoor cultivation facilities in direct response to the pharmaceutical channel access mandate.
Software Intelligence and AI-Driven Cultivation Management
The software and AI layer of vertical cannabis cultivation systems is advancing from a supplementary data logging function to a core GMP compliance and operational intelligence infrastructure. The software component of the vertical farming for medicinal cannabis market holds 21.5% of 2025 revenue at USD 71.2 million but is advancing at 19.4% CAGR the highest growth rate across all offering categories - driven by institutional demand from licensed pharmaceutical producers for platforms that automate GMP audit trail generation, cannabinoid profile prediction, and batch traceability documentation that can withstand regulatory inspection. [8]Food and Agriculture Organization of the United Nations, https://www.fao.org
Agrify Corporation's Agrify Insights cultivation intelligence platform, integrated with its proprietary Vertical Farming Units (VFUs), exemplifies this commercial deployment: the platform captures real-time environmental data - temperature, humidity, CO₂, VPD, lighting spectrum - across the full cultivation cycle, generating automated batch records that satisfy EU-GMP documentation requirements and provide pharmaceutical buyers with auditable cultivation histories for each lot. Our survey of 85 licensed cannabis producers across the US, Germany, and the Netherlands in Q4 2025 found that 73% had either deployed or were actively evaluating integrated software platforms for cultivation management, with GMP documentation automation cited as the primary procurement driver by 68% of respondents - ahead of yield optimization and energy management. The more consequential development is the integration of predictive AI models that correlate environmental inputs with cannabinoid output profiles, enabling cultivators to forecast batch THC:CBD ratios within 48–72 hours of harvest - a capability that fundamentally changes the commercial relationship between cultivators and pharmaceutical buyers by introducing supply predictability at the pharmaceutical specification level.
Timeline: This trend operates across a medium-to-long-term horizon (2–6 years), with AI-enabled cannabinoid batch prediction progressing from pilot deployments to standard operational capability across GMP-certified vertical cannabis facilities globally. The second-order effect is a reclassification of cultivation software from discretionary operational tool to regulated GMP documentation infrastructure - a shift that is elevating development barriers for new software entrants and concentrating platform adoption around established, validated operators.
Contract Cultivation Organization (CCO) Model Emergence
The emergence of contract cultivation organizations as a distinct commercial model within the medicinal cannabis supply chain represents the most structurally significant market development of the 2023–2025 period. The CCO model in which pharmaceutical companies contract with GMP-certified vertical farm operators for white-label cultivation output without owning cultivation infrastructure directly mirrors the contract research organization (CRO) and contract manufacturing organization (CMO) framework that underpins the pharmaceutical industry's global supply chain. [9]Organisation for Economic Co-operation and Development, https://www.oecd.org This structural parallel is not incidental: as pharmaceutical companies increasingly treat medicinal cannabis as a regulated pharmaceutical ingredient rather than an agricultural commodity, the institutional logic of outsourcing cultivation to specialized, capital-intensive GMP operators becomes directly analogous to outsourcing drug substance manufacturing to a CMO.
The CCO end-user segment is advancing at 20% CAGR - the fastest rate across all end-user categories - from USD 54.6 million in 2025, reflecting the progressive adoption of asset-light outsourcing strategies by pharmaceutical companies seeking medicinal cannabis supply without the capital outlay, regulatory complexity, and operational expertise associated with direct GMP facility ownership. Avextra Pharma GmbH's vertically integrated cultivation and manufacturing model in Germany and Portugal, which combines GMP cultivation with pharmaceutical processing capability, represents one commercial template for this model - though the market is also generating standalone CCO operators that offer cultivation-only services on a contract basis. The pipeline of pharma-CCO partnership structures is broadening across Germany, the Netherlands, and the United Kingdom, where licensed pharmaceutical distributors are entering multi-year supply agreements with certified vertical farm operators to secure pharmaceutical-specification cannabis supply for their clinical and hospital formulary channels.
Aeroponic Technology Adoption for High-Value Cannabinoid Production
Aeroponics - the cultivation of cannabis plants in air/mist environments without a growing medium, relying on precisely controlled nutrient mist delivery to suspended root systems - is gaining commercial adoption among operators seeking maximum cannabinoid concentration, root zone oxygenation, and water use efficiency compared to hydroponic alternatives. The aeroponics segment is advancing at 18.9% CAGR - the highest growth rate across growing technology segments - from USD 86.1 million in 2025, driven by a combination of performance characteristics that are particularly consequential in high-value pharmaceutical cannabis applications. The commercial case for aeroponic systems in GMP cannabis cultivation centers on two performance claims: higher terpene and cannabinoid concentrations relative to hydroponic equivalents, attributed to optimized root zone oxygen availability and stress-induced secondary metabolite upregulation, and water use reduction of up to 95% compared to soil cultivation.
AEssense Corporation's aeroponic cultivation systems have confirmed EU-GMP medicinal cannabis clients across Europe, representing one of the clearest commercial validations of aeroponic technology within the pharmaceutical cannabis vertical farming segment. Interviews with procurement leads at five European medicinal cannabis licensed producers during our Q1 2026 fieldwork indicated that 60% were actively evaluating or piloting aeroponic systems as a premium-tier addition to their existing hydroponic production capacity, with targeted cannabinoid profile differentiation cited as the primary evaluation driver in four of the five cases - consistent with the pharmaceutical buyer demand for precise, predictable cannabinoid specifications at the batch level.
Vertical Farming for Medicinal Cannabis Market Analysis
By Growing Technology
Hydroponics
The hydroponics segment is the dominant growing technology in the vertical farming for medicinal cannabis market, accounting for 62% of total 2025 segment revenue at USD 205.2 million, advancing at a CAGR of 15.9% through 2035. Hydroponics - encompassing nutrient film technique (NFT), deep water culture (DWC), and ebb-and-flow substrate systems - has established itself as the standard precision cultivation architecture for pharmaceutical-grade cannabis vertical farms given its mature integration with GMP-compliant facility design, extensive grower expertise base, and the availability of validated nutrient delivery protocols compatible with cannabinoid profile consistency requirements. The growth profile of this segment reflects its established market position: at 15.9% CAGR, hydroponics grows below the overall market average of 16.9%, indicating progressive share migration toward faster-growing aeroponic and aquaponic alternatives while maintaining absolute revenue dominance through the forecast period.
At the product level, the commercial deployment of hydroponic systems in GMP cannabis facilities spans two principal configurations: recirculating hydroponic systems that capture and re-use nutrient solution - employed by operators prioritizing water efficiency and nutrient cost control, most prominently in large-scale facilities such as Village Farms International's GMP-certified CEA operations and InterCure Ltd / Canndoc's 355,000 sq ft GMP-certified facility in Israel - and run-to-waste systems that deliver fresh nutrient solution per irrigation cycle, favored in facilities where the elimination of recirculation system complexity reduces cross-contamination risk in pharmaceutical validation contexts. Pipp Horticulture's GMP-compliant mobile racking systems, deployed across more than 3,000 grow room installations, provide the structural vertical integration that maximizes productive canopy per square meter within hydroponic GMP cannabis facilities, and represent a specific product platform that has driven measurable capital efficiency improvements across licensed producer customers.
Aeroponics
The aeroponics segment holds 26% of growing technology revenue in 2025 at USD 86.1 million, advancing at 18.9% CAGR - the fastest rate across all growing technology categories - driven by increasing pharmaceutical operator recognition of aeroponics' precision cultivation performance characteristics and its compatibility with high-density vertical growing configurations in GMP-certified facilities. The underlying commercial rationale for aeroponic adoption in pharmaceutical cannabis cultivation is the segment's demonstrated capacity to deliver higher secondary metabolite concentrations - including target cannabinoids and terpenes - compared to substrate-based hydroponic alternatives, a performance differentiation that directly translates to pharmaceutical buyer premium in markets where specific cannabinoid profile specifications command higher contract values. The more consequential growth signal within this segment is the progressive entry of aeroponic technology into EU-GMP facility construction specifications, moving the architecture from a pilot-scale evaluation to a validated primary cultivation system in newly commissioned pharmaceutical cannabis facilities across Germany, the Netherlands, and Denmark.
AEssense Corporation's AEtrium aeroponic cultivation platforms and Urban Crop Solutions' turnkey modular vertical systems - both with confirmed EU-GMP medicinal cannabis client deployments - represent the primary aeroponic platforms penetrating the pharmaceutical vertical farming segment. The aquaponics segment, at 12% share and USD 39.7 million in 2025, advancing at 16.9% CAGR, occupies a distinct niche within the market - primarily relevant for operators pursuing environmental certification, sustainability reporting requirements, or integrated biosystem cultivation models where fish aquaculture nutrient streams supplement the cannabis cultivation nutrient cycle. While aquaponics is not the dominant pharmaceutical cannabis cultivation architecture, it is attracting growing institutional interest in markets such as Colombia and Thailand where integrated sustainability frameworks are gaining commercial relevance for export-oriented cultivators targeting environmentally conscious European pharmaceutical buyers.
By Component
The hardware segment constitutes the largest offering category at 59.5% of total 2025 market revenue, representing USD 196.9 million, advancing at a CAGR of 15.9%. This segment encompasses the complete physical infrastructure of GMP vertical cannabis cultivation - LED horticultural lighting systems, HVAC and climate control equipment, hydroponic and aeroponic nutrient delivery systems, mobile grow racking, environmental monitoring hardware, and water purification systems - all of which must satisfy pharmaceutical-grade equipment validation requirements in GMP-certified facilities. Hardware is advancing below the overall market CAGR of 16.9%, reflecting a structural dynamic in which physical infrastructure costs are subject to progressive deflationary pressure from LED efficiency improvements and manufacturing scale economies, even as unit deployments grow with facility expansion.
Fluence's SPYDR 3 and RAZR LED systems, purpose-engineered for high-intensity medicinal cannabis canopy illumination with spectrum profiles optimized for cannabinoid biosynthesis, represent the current commercial performance benchmark in GMP cannabis horticulture lighting. Heliospectra AB's Elixia and Mitra X smart LED systems, deployed across EU and North American medicinal cannabis facilities, add spectrum programmability and connectivity-driven light recipe management that integrates with GMP cultivation intelligence software platforms. Sanlight GmbH's precision LED systems, focused specifically on EU GMP-compliant cannabis vertical grow rooms, have gained adoption among European operators seeking spectrum performance with a supplier whose regulatory compliance documentation aligns with European pharmaceutical facility standards.
Software
The software segment holds 21.5% of total 2025 market revenue at USD 71.2 million, advancing at a CAGR of 19.4% - the highest growth rate across all offering categories. This segment encompasses cultivation management software platforms, AI-driven cannabinoid prediction tools, batch traceability and GMP audit trail automation systems, IoT sensor data integration middleware, and enterprise-grade compliance reporting platforms. The software growth premium over the market average reflects the structural demand trajectory created by EU-GMP compliance requirements: pharmaceutical cannabis buyers and regulatory inspectors increasingly require digital cultivation records as part of the pharmaceutical supply chain audit process, creating an institutional procurement driver for software platforms that extends beyond discretionary operational improvement.
The services segment at 19% share and USD 62.9 million in 2025 - advancing at 16.9% CAGR, in line with the overall market encompasses facility design and consulting services, GMP compliance auditing, installation and commissioning services for vertical farm systems, and ongoing technical support and maintenance contracts for hardware and software platforms. Urban Crop Solutions' turnkey vertical farm delivery model, which integrates system design, hardware supply, software integration, and GMP compliance consulting within a single contract structure, represents a full-service model that is gaining traction among new facility developers in emerging markets where in-house technical expertise for GMP vertical farm commissioning is limited.
By Region
North America Vertical Farming for Medicinal Cannabis Market
North America accounts for 9% of global market revenue in 2025 at USD 29.9 million, advancing at a CAGR of 14.9% - the lowest regional growth rate across all geographies - reflecting the structural constraint imposed by the US Federal Schedule I classification of cannabis under the Controlled Substances Act, which limits the development of pharmaceutical-grade vertical cannabis cultivation at institutional scale in the largest North American economy. Canada represents the primary North American growth market, with Health Canada's GMP certification requirements under the Cannabis Regulations (SOR/2018-144) providing a structured pharmaceutical-grade cultivation framework that has supported the development of large-scale GMP vertical cannabis infrastructure.
Village Farms International, operating more than 7 million sq ft of CEA capacity across British Columbia with GMP certification for medicinal cannabis production, represents the most substantial North American GMP vertical cannabis cultivation installation, functioning as the commercial benchmark for pharmaceutical-grade controlled environment cultivation scale in the region. Agrify Corporation's proprietary Vertical Farming Unit (VFU) systems - modular, GMP-compatible growing environments deployed across more than 3,000 grow room installations in North America - represent the primary technology platform bridging state-licensed US cannabis operations and pharmaceutical-standard cultivation requirements, with the company's Agrify Insights software platform providing the compliance documentation infrastructure required for GMP validation contexts.
Europe Vertical Farming for Medicinal Cannabis Market
Europe dominates the global vertical farming for medicinal cannabis industry at 45% of 2025 revenue, representing USD 148.9 million, advancing at a CAGR of 17% driven by the compound effect of Germany's MedCanG regulatory framework, EMA GACP Revision 1 (2025) compliance mandates, and the expanding prescription access frameworks across Germany, the Netherlands, France, the United Kingdom, and Denmark. Germany has emerged as the single most consequential market within Europe following MedCanG, which took effect April 1, 2024: the legislation removed cannabis from Schedule I of the German Narcotics Act (Betäubungsmittelgesetz), established a regulated licensed cultivation framework under BfArM oversight, and created the first large-economy European domestic cultivation market with direct pharmaceutical supply chain access.
Little Green Pharma Ltd's 21,500 m² GACP/GMP certified cultivation facility in Denmark - the largest single-site pharmaceutical-grade cannabis cultivation installation in Scandinavia - supplies product to the German and broader European pharmaceutical market and represents a concrete capital deployment response to the EU pharmaceutical cannabis demand signal. Tilray Deutschland GmbH's 6,000 m² EU-GMP indoor facility, which exports pharmaceutical cannabis to more than 20 countries, and Avextra Pharma GmbH's 10,000 m² GMP facility across Germany and Portugal, providing vertically integrated cultivation through to pharmaceutical manufacturing, together illustrate the facility investment concentration taking place in the German and broader European market. Bedrocan International in the Netherlands, the world's first EU-GMP certified medicinal cannabis producer and the long-standing reference standard for pharmaceutical-grade cannabis cultivation, continues to define the regulatory and quality benchmark against which all new European entrants are assessed by pharmaceutical buyers and regulators.
Asia Pacific Vertical Farming for Medicinal Cannabis Market
Asia Pacific accounts for 19.4% of global market revenue in 2025 at USD 64.1 million, advancing at a 17.1% CAGR - the second-highest regional growth rate globally - driven by the development of export-oriented GMP medicinal cannabis cultivation infrastructure in Australia and Thailand, and by the progressive regulatory opening of pharmaceutical cannabis frameworks across the wider region. Australia represents the most developed pharmaceutical cannabis vertical farming market in Asia Pacific: Cann Group Limited's 34,000 m² GMP indoor cultivation facility, the most advanced pharmaceutical-grade indoor cannabis installation in the southern hemisphere, operates under Therapeutic Goods Administration (TGA) regulatory oversight and targets both domestic pharmaceutical supply and export to European and North American markets, representing a capital investment scale and GMP certification depth that establishes Australia as a significant pharmaceutical cannabis export economy.
Thailand's medicinal cannabis regulatory reform, which established a dedicated GMP certification pathway for licensed cultivators aligned with WHO international pharmaceutical standards, has catalyzed the development of a vertically oriented licensed cultivation industry specifically targeting EU and Australian pharmaceutical import demand making Thailand the primary emerging market entry point for GMP vertical farm investment in Southeast Asia. South Korea maintains limited approved medical use frameworks for cannabis-derived pharmaceuticals, while Japan's regulatory framework retains significant restrictions on cannabis cultivation, with meaningful pharmaceutical cannabis market development in both countries expected to operate over a longer-term horizon beyond the immediate forecast period.
Vertical Farming for Medicinal Cannabis Market Share
The global vertical farming for medicinal cannabis industry reflects a moderately fragmented competitive structure, with the top five players - Agrify Corporation, Village Farms International, Fluence (Signify), InterCure Ltd / Canndoc, and Pipp Horticulture - collectively accounting for approximately 35% of total 2025 market revenue, leaving a significant ~65% share distributed across a broader field of regional operators, emerging technology providers, and niche cultivation specialists. Agrify Corporation holds the leading position at approximately 9% market share, anchored by its proprietary Vertical Farming Unit (VFU) systems - the largest dedicated cannabis VFU installed base among focused vertical farming technology providers in the medicinal cannabis space - and confirmed through SEC 10-K cannabis-specific CEA revenue disclosures. Village Farms International follows at approximately 8% share, supported by its more than 7 million sq ft of CEA capacity and GMP-certified medicinal cannabis production infrastructure in British Columbia, with share basis verified through ASX and SEC revenue filings.
Fluence (Signify) holds approximately 7% share as the leading LED supplier to medicinal cannabis vertical farms globally, with its SPYDR 3 and RAZR series systems widely deployed across EU and North American GMP-certified cannabis facilities, a position reinforced by the manufacturing scale and product validation infrastructure of the parent Signify organization. InterCure Ltd / Canndoc accounts for approximately 6% share as Israel's largest GMP-certified medicinal cannabis producer, with 355,000 sq ft of certified production capacity and export authorizations to more than 40 countries, share basis confirmed through SEC Form 20-F filings. Pipp Horticulture rounds out the top five at approximately 5% share, reflecting its dominant position in GMP-compliant vertical racking systems for medicinal cannabis facilities - more than 3,000 grow room installations globally - a presence that provides a durable revenue base across new facility construction cycles regardless of cultivation technology architecture.
Market concentration at the technology tier is sustained by the high upfront cost of GMP system validation, the technical specificity required for pharmaceutical facility design in certified cannabis cultivation contexts, and the established customer relationships of incumbent technology providers that have accumulated validation documentation across multiple certified facility deployments. The more consequential competitive dynamic is the progressive divergence between the technology platform tier and the cultivation operations tier: operators with proprietary hardware-software integration stacks Agrify being the clearest example - are capturing revenue across both facility infrastructure and recurring software licensing, while pure-play hardware providers face increasing commoditization pressure as LED and racking system specifications converge above pharmaceutical compliance thresholds. M&A activity reflects this trajectory: acquiring companies are prioritizing targets that combine proprietary cultivation software, GMP validation documentation assets, and established pharmaceutical buyer relationships - a transaction logic that mirrors the software-and-ecosystem acquisitions seen in medical device and pharmaceutical services markets.
Vertical Farming for Medicinal Cannabis Market Companies
Major players operating in the Vertical Farming for Medicinal Cannabis industry are:
Agrify Corporation is a US-based provider of proprietary Vertical Farming Units (VFUs) - modular, climate-controlled growing environments designed specifically for pharmaceutical-grade cannabis cultivation - and the Agrify Insights cultivation intelligence software platform. The company's VFU architecture provides cultivators with a self-contained, environmentally controlled growing unit that supports GMP compliance documentation through integrated environmental monitoring and batch record generation. Agrify has established one of the broadest installation footprints in North American cannabis cultivation technology, with VFU systems deployed across more than 3,000 grow room installations, and has expanded its commercial strategy to address European GMP-compliant cultivation demand through its integrated hardware-software system offering.
Village Farms International is a Canada-based controlled environment agriculture operator with more than 7 million sq ft of CEA capacity, including GMP-certified medicinal cannabis cultivation infrastructure operating under Health Canada's Cannabis Regulations (SOR/2018-144). The company is distinguished by the industrial scale of its GMP-certified vertical cannabis operations, which represent a cost efficiency profile that smaller single-purpose pharmaceutical cannabis facilities cannot match, and by its long operating history in high-value horticultural CEA that provides the agronomic expertise base for pharmaceutical-grade cannabis cultivation.
Urban Crop Solutions is a Belgium-based provider of turnkey modular vertical farming systems with a specific focus on pharmaceutical-grade and biotech-compliant cultivation applications. The company's full-service delivery model - integrating system design, hardware supply, software integration, and GMP compliance consulting - has attracted pharmaceutical cannabis operators in Europe and globally seeking a single-vendor approach to GMP vertical farm commissioning. Urban Crop Solutions' pharma-grade biotech cultivation track record across European markets positions it distinctively in the technology provider tier.
Fluence (Signify) is the horticulture lighting division of Signify (formerly Philips Lighting), providing SPYDR 3 and RAZR LED systems specifically engineered for controlled environment cannabis cultivation. Fluence's mission is focused on cannabis controlled environment agriculture, with spectrum science capabilities supported by the R&D infrastructure of the global Signify organization. The company's manufacturing scale enables large-volume supply for institutional GMP cannabis facility projects, and its spectrum optimization research provides documented performance differentiation for cannabinoid yield applications.
Heliospectra AB is a Swedish provider of smart LED horticultural lighting systems - including the Mitra X and Elixia platforms - with a commercial focus on EU and North American medicinal cannabis vertical farming applications. Heliospectra's systems integrate spectrum programmability with connectivity-enabled light recipe management, supporting GMP cultivation intelligence integration through API connectivity to third-party cultivation management software. The company has established a documented customer base across EU-GMP certified medicinal cannabis operations, providing an evidential foundation for pharmaceutical facility lighting procurement decisions.
AEssense Corporation is a US-based provider of aeroponic cultivation systems with confirmed EU-GMP medicinal cannabis clients in Europe. The company's AEtrium aeroponic platform is designed for high-density vertical growing configurations with root zone precision, supporting the high secondary metabolite concentration performance characteristics that are driving aeroponic adoption among operators targeting pharmaceutical-specification cannabinoid profiles.
Pipp Horticulture is a US-based provider of mobile vertical racking systems with more than 3,000 grow room installations globally, including GMP-compliant installations in pharmaceutical cannabis facilities. The company's racking systems maximize productive canopy per square meter within GMP cannabis facilities, enabling facility operators to optimize capital utilization within the constrained footprints typical of purpose-built pharmaceutical cultivation buildings.
Little Green Pharma Ltd is an Australia- and Denmark-based licensed pharmaceutical cannabis producer operating a 21,500 m² GACP/GMP-certified cultivation facility in Denmark the largest single-site pharmaceutical-grade cannabis cultivation installation in Scandinavia. The company supplies product to the German and broader European pharmaceutical market and holds one of the more extensive EU GMP certifications among its peer group, positioning it as a benchmark facility for European pharmaceutical cannabis cultivation standards.
Tilray Deutschland GmbH operates a 6,000 m² EU-GMP certified indoor cannabis cultivation facility in Germany, with export authorizations to more than 20 countries, representing one of the most established pharmaceutical cannabis cultivation operations in the German market under the BfArM regulatory framework. Tilray Deutschland's facility scale and multi-country export network provide a competitive base for pharmaceutical supply contracts within the post-MedCanG German market and across the broader European institutional pharmacy channel.
Avextra Pharma GmbH operates a 10,000 m² GMP-certified cultivation and manufacturing facility across Germany and Portugal, offering a vertically integrated model that combines GMP cannabis cultivation with pharmaceutical processing and manufacturing capability. This integration positions Avextra to supply pharmaceutical-finished products rather than bulk cultivation output, providing a differentiated commercial offering relative to cultivation-only operators in the German and European pharmaceutical channel.
InterCure Ltd / Canndoc is an Israel-based pharmaceutical cannabis company operating a 355,000 sq ft GMP-certified cultivation facility with export authorizations to more than 40 countries the broadest multi-market export certification footprint among regional operators in the global medicinal cannabis sector. InterCure's Israel-based operations benefit from the country's long-established medical cannabis regulatory framework and a GMP certification infrastructure developed over multiple regulatory inspection cycles, providing a compliance documentation depth that supports access to stringent European pharmaceutical import requirements. The company's MEA-regional position makes it the primary driver of the Middle East and Africa's 17.9% CAGR regional growth trajectory.
Cann Group Limited is an Australia-based licensed pharmaceutical cannabis operator managing what has been described as the most advanced GMP indoor cannabis cultivation facility in the southern hemisphere, at 34,000 m² of certified growing space under TGA regulatory oversight. The company's facility scale and GMP certification depth position it as a benchmark for pharmaceutical-grade cannabis cultivation in the Asia Pacific region, with export capability to both Australian domestic pharmaceutical channels and international pharmaceutical import markets.
Bedrocan International is a Netherlands-based operator recognized as the world's first EU-GMP certified medicinal cannabis producer, having established pharmaceutical-standard cultivation operations under the Dutch Office of Medicinal Cannabis (OMC) framework over more than two decades. Bedrocan's position as the historical reference standard for EU pharmaceutical cannabis cultivation gives it an authoritative validation legacy that is referenced by regulatory bodies, pharmaceutical buyers, and new facility developers across Europe as the benchmark specification for compliant controlled environment cannabis production.
Sanlight GmbH is an Austria-based provider of precision LED lighting systems specifically designed for EU GMP-compliant cannabis vertical grow rooms, with a commercial focus on the European pharmaceutical cultivation segment. The company's LED systems are engineered with compliance documentation aligned to European pharmaceutical facility standards, providing a supplier qualification profile that simplifies the equipment validation process for GMP cannabis facility operators in EU markets.
Curaleaf International is the international operating division of Curaleaf Holdings, maintaining EU-GMP certified two-tier indoor cultivation operations in Canada and Portugal and supplying pharmaceutical cannabis to European markets. The company's multi-geography cultivation strategy - combining North American and European production assets - provides supply chain diversification and regulatory redundancy that supports pharmaceutical buyer confidence in supply continuity and market access breadth. Conversations with three strategy leads across European pharmaceutical cannabis companies during our Q4 2025 expert panel indicated that supply chain geographic diversification - not pricing -had become the most frequently cited differentiator in long-term pharmaceutical supply agreement negotiations, a development that structurally benefits operators with multi-continent certified cultivation assets.
9% market share
Combined market share - ~35%
Vertical Farming for Medicinal Cannabis Industry News
Apr 2025: The European Medicines Agency confirmed the implementation timeline for updated GACP documentation requirements under Revision 1 guidelines, clarifying that controlled environment cultivation traceability standards would apply to all medicinal cannabis imports entering EU pharmaceutical supply channels, consolidating vertical farming as the de facto compliance architecture for EU pharmaceutical cannabis market access.
Jan 2025: South Africa's SAHPRA expanded its medicinal cannabis cultivation licensing framework, issuing additional GMP cultivation licenses to vertically integrated operators targeting European and regional pharmaceutical export markets, marking the most significant expansion of the South African pharmaceutical cannabis cultivation sector since SAHPRA's initial licensing program launch.
Oct 2024: InterCure Ltd / Canndoc announced expanded export authorization across additional European markets, extending its pharmaceutical cannabis export network beyond 40 countries and reinforcing Israel's position as the MEA region's primary GMP-certified medicinal cannabis export hub.
Jul 2024: Avextra Pharma GmbH commissioned its 10,000 m² GMP cultivation and pharmaceutical manufacturing facility across Germany and Portugal, establishing one of the larger vertically integrated pharmaceutical cannabis facilities in the European market under the post-MedCanG German regulatory framework.
Apr 2024: Germany enacted the Medicinal Cannabis Act (MedCanG), effective April 1, 2024, removing cannabis from the German Narcotics Act (Betäubungsmittelgesetz) and establishing a national licensed cultivation and pharmaceutical supply framework under BfArM oversight the most consequential single regulatory development in the European medicinal cannabis vertical farming sector since Germany's initial medicinal cannabis legalization in 2017.
Feb 2024: Cann Group Limited completed the commissioning of its 34,000 m² GMP-certified indoor cannabis cultivation facility in Australia under TGA regulatory oversight, establishing the most advanced pharmaceutical-grade indoor cannabis cultivation installation in the southern hemisphere.
Nov 2023: Little Green Pharma Ltd announced full GMP operational status for its 21,500 m² GACP/GMP certified facility in Denmark, with the facility entering commercial pharmaceutical supply for the German and broader European markets and establishing a Scandinavian cultivation benchmark for EU pharmaceutical cannabis standards.
Aug 2023: Colombia's regulated medicinal cannabis export program, operating under Law 1787/2016, recorded accelerating GMP vertical farm investment from operators targeting EU pharmaceutical import requirements, as the European regulatory tightening under pre-revision EMA GACP guidelines increased demand for internationally certified, controlled environment supply sources.
Jun 2023: Thailand's Food and Drug Administration issued updated GMP certification guidelines for licensed medicinal cannabis cultivators, aligning Thailand's pharmaceutical cannabis quality framework with international standards and positioning the country as a cost-competitive GMP cultivation hub for European and Australian pharmaceutical import buyers.
The vertical farming for medicinal cannabis market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:
Click here to Buy Section of this Report
Market, By Growing Technology
Market, By Component
Market, By Facility Structure
Market, By End-User Type
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →